American Heart Journal
Volume 158, Issue 4 , Pages 653-658 , October 2009

Blood transfusion for acute decompensated heart failure—friend or foe?

  • Moshe Garty, MD

      Affiliations

    • Recanati Center for Medicine and Research, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Eytan Cohen, MD

      Affiliations

    • Recanati Center for Medicine and Research, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Alexander Zuchenko, MD

      Affiliations

    • Recanati Center for Medicine and Research, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Solomon Behar, MD

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel
    • ,
  • Valentina Boyko, MSc

      Affiliations

    • Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel
    • ,
  • Zaza Iakobishvili, MD, PhD

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
    • ,
  • Moshe Mittelman, MD

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Medicine, Tel Aviv Sourasky Medical Center, Israel
    • Corresponding Author InformationReprint requests: Moshe Garty, MD, Recanati Center for Medicine and Research, Rabin Medical Center, Beilinson Campus, Petah Tiqwa 49100, Israel.
    • ,
  • Alexander Battler, MD

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
    • ,
  • Avraham Shotan, MD

      Affiliations

    • Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel
    • ,
  • Shmuel Gottlieb, MD

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel
    • Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
    • ,
  • Avraham Caspi, MD

      Affiliations

    • Department of Cardiology, Kaplan Medical Center, Rehovot, Israel
    • ,
  • David Hasdai, MD

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
    • ,
  • for the Heart Failure Survey in ISrael (HFSIS) Investigators

Received 7 June 2009 ,Accepted 6 August 2009.

References 

  1. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008;13:387–392
  2. Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008;13:379–386
  3. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818–827
  4. Dunlay SM, Weston SA, Redfield MM, et al. Anemia and heart failure: a community study. Am J Med. 2008;121:726–732
  5. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113:2713–2723
  6. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–1744
  7. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–1780
  8. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol. 2007;49:753–762
  9. Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007;154:645.e9–645.e15
  10. Ghali JK, Anand IS, Abraham WT, et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–535
  11. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52:501–511
  12. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225–1227
  13. Toblli JE, Lombrana A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–1665
  14. Gerber DR. Transfusion of packed red blood cells in patients with ischemic heart disease. Crit Care Med. 2008;36:1068–1074
  15. Alexander KP, Chen AY, Wang TY, et al. Transfusion practice and outcomes in non–ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155:1047–1053
  16. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med. 1992;116:93–402
  17. McMahon TJ, Moon RE, Luschinger BP, et al. Nitric oxide in the human respiratory cycle. Nat Med. 2002;8:711–717
  18. Fransen E, Maessen J, Dentener M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116:1233–1239
  19. Reynolds JD, Ahearn GS, Angelo M, et al. S-Nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci USA. 2007;104:17058–17062
  20. Garty M, Shotan A, Gottlieb S, et al. The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure Survey in Israel—HFSIS 2003. Isr Med Assoc J. 2007;9:227–233
  21. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail. 2002;4:11–22
  22. Hébert PC, Wells G, Tweeddale M, et al. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med. 1997;155:1618–1623
  23. Hébert PC, Yetisir E, Martin C, et al. Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?. Crit Care Med. 2001;29:227–234
  24. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230–1236
  25. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555–1562
  26. Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non–ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1490–1495
  27. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042–2049
  28. Task Force for Diagnosis and Treatment of Non–ST-Segment Elevation Acute Coronary Syndromes of European Society of CardiologyBassand JP, Hamm CW, et al. Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–1660
  29. Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–463
  30. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–474
  31. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals. Arch Intern Med. 2005;165:1469–1477
  32. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167:1493–1502
  33. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388–2442
  34. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;[Epub ahead of print]

PII: S0002-8703(09)00611-5

doi: 10.1016/j.ahj.2009.08.001

American Heart Journal
Volume 158, Issue 4 , Pages 653-658 , October 2009

Article Tools

* Image Usage & Resolution